How have ENGNW shares performed in 2024?

enGene's stock was trading at $0.85 on January 1st, 2024. Since then, ENGNW shares have increased by 400.0% and is now trading at $4.25. View the best growth stocks for 2024 here .

Are investors shorting enGene?

enGene saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,700 shares, a decline of 76.4% from the March 31st total of 7,200 shares. Based on an average trading volume of 40,600 shares, the short-interest ratio is currently 0.0 days. View enGene's Short Interest .

Is enGene a good dividend stock?

enGene (NASDAQ:ENGNW) pays an annual dividend of $1.58 per share and currently has a dividend yield of 0.00%.

How do I buy shares of enGene?

Shares of ENGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENGNW

enGene (ENGNW) Stock Price, News & Analysis

→ Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad)

Free ENGNW Stock Alerts

$4.25

0.00 (0.00%)

(As of 05/7/2024 ET)

Compare

Today's Range: $4.25
▼
$4.25
50-Day Range: $3.52
▼
$6.38
52-Week Range: $0.39
▼
$6.50

Volume: 13 shs
Average Volume: 36,184 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get enGene alerts:

Ad Crypto 101 Media

Incredible Opportunity to Retire FAST!

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

ENGNW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENGNW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive ENGNW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ENGNW
CUSIP: N/A
CIK: 1980845
Web: www.engene.com
Phone: 514-332-4888
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: N/A
Beta: N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Jason D. Hanson Esq. (Age 55)
J.D., CEO & Director
Comp: $656.58k
Dr. Alex Nichols Ph.D. (Age 38)
President & COO
Comp: $504.44k
Dr. James C. Sullivan M.Sc. (Age 45)
Ph.D., Chief Scientific Officer
Comp: $524.29k
Dr. Anthony T. Cheung Ph.D. (Age 52)
Co-Founder & CTO
Comp: $341.75k
Mr. John C. Brown D.Sc.
FRSC, Ph.D., Co-Founder and Member of Scientific Advisory Board
Mr. David Ryan Daws (Age 50)
CFO & Head of Business Development
Mr. Lee G. Giguere (Age 43)
Chief Legal Officer & Corporate Secretary
Ms. Sharon Tan
VP of Project Management & Head of Program Management
Dr. Richard P. Bryce MBChB (Age 67)
MFPM, MRCGP, Chief Medical Officer
Dr. Raj Pruthi M.D.
Senior VP of Urologic Oncology & Clinical Development

Key Competitors

View All Competitors

ENGNW Stock Analysis - Frequently Asked Questions

How have ENGNW shares performed in 2024?: enGene's stock was trading at $0.85 on January 1st, 2024. Since then, ENGNW shares have increased by 400.0% and is now trading at $4.25.
View the best growth stocks for 2024 here.
Are investors shorting enGene?: enGene saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,700 shares, a decline of 76.4% from the March 31st total of 7,200 shares. Based on an average trading volume of 40,600 shares, the short-interest ratio is currently 0.0 days.
View enGene's Short Interest.
Is enGene a good dividend stock?: enGene (NASDAQ:ENGNW) pays an annual dividend of $1.58 per share and currently has a dividend yield of 0.00%.
How do I buy shares of enGene?: Shares of ENGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENGNW) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial